Pregnane-2,3-dione | 33041-33-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Pregnane-2,3-dione
• 英文别名: (8S,9S,10S,13R,14S,17S)-17-ethyl-10,13-dimethyl-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-2,3-dione
• CAS: 33041-33-7
• 化学式: C₂₁H₃₂O₂
• 分子量: 316.5
• InChiKey: ZAWFKXSZCOAQKP-HUOPTEJRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Regulation of gene expression using single-chain, monomeric, ligand dependent polypeptide switches
  申请人：Novartis AG

  公开号：EP1908835A2

  公开（公告）日：2008-04-09

  The invention relates to single chain, monomeric polypeptide gene switches. The gene switches include ligand binding domains and at least one functional domain. Preferred functional domains are DNA binding domains. The invention also relates to methods regulating gene function using these switches

  本发明涉及单链、单体多肽基因开关。基因开关包括配体结合结构域和至少一个功能结构域。首选的功能域是 DNA 结合域。本发明还涉及使用这些开关调节基因功能的方法
• Plasmid mediated supplementation for treating chronically ill subjects
  申请人：ADViSYS, Inc.

  公开号：US20040057941A1

  公开（公告）日：2004-03-25

  The present invention pertains to compositions and methods for plasmid-mediated supplementation. The compositions and method are useful for retarding the growth of the tumor, and retarding cachexia, wasting, anemia and other effects that are commonly associated in cancer bearing animals. Overall, the embodiments of the invention can be accomplished by delivering an effective amount of a nucleic acid expression construct that encodes a GHRH or functional biological equivalent thereof into a tissue of an animal and allowing expression of the encoded gene in the animal. For example, when such a nucleic acid sequence is delivered into the specific cells of the animal tissue specific constitutive expression is achieved. Furthermore, external regulation of the GHRH or functional biological equivalent thereof gene can be accomplished by utilizing inducible promoters that are regulated by molecular switch molecules, which are given to the animal. The preferred method to deliver the constitutive or inducible nucleic acid encoding sequences of GHRH or the functional biological equivalents thereof is directly into the cells of the animal by the process of in vivo electroporation. In addition, a treatment for retarding the growth of the tumor, and retarding cachexia or the wasting effects that are commonly associated with tumors is achieved by the delivery of recombinant GHRH or biological equivalent into the animal.

  本发明涉及质粒介导的补充剂的组合物和方法。本发明的组合物和方法有助于延缓肿瘤的生长，延缓恶病质、消瘦、贫血和其他通常与癌症动物相关的影响。总之，本发明的实施方案可以通过将有效量的编码 GHRH 或其功能生物等效物的核酸表达构建体递送到动物的组织中，并允许编码基因在动物体内表达来实现。例如，当这种核酸序列被输送到动物组织的特定细胞中时，可实现特定的组成型表达。此外，GHRH 或其功能生物等效基因的外部调控可通过利用诱导型启动子来实现，诱导型启动子由分子开关分子调控，而诱导型启动子则给予动物。将 GHRH 或其功能生物等效物的组成型或诱导型核酸编码序列直接导入动物细胞的首选方法是体内电穿孔法。此外，通过向动物体内递送重组 GHRH 或生物等效物，还可实现延缓肿瘤生长、延缓恶病质或通常与肿瘤相关的消瘦效应的治疗。
• Composition and method to alter lean body mass and bone properties in a subject
  申请人：Baylor College of Medicine

  公开号：US20040138111A1

  公开（公告）日：2004-07-15

  The present invention pertains to a method for decreasing the body fat proportion, increasing lean body mass (“LBM”), increasing bone density, or improving the rate of bone healing, or all, of a subject. Overall, the embodiments of the invention can be accomplished by delivering a heterologous nucleic acid sequence encoding GHRH or functional biological equivalent thereof into the cells of the subject and allowing expression of the encoded gene to occur while the modified cells are within the subject. For instance, when such a nucleic acid sequence is delivered into the specific cells of the subject tissue specific constitutive expression is achieved. Furthermore, external regulation of the GHRH or functional biological equivalent thereof gene can be accomplished by utilizing inducible promoters that are regulated by molecular switch molecules, which are given to the subject. The preferred method to deliver the constitutive or inducible nucleic acid encoding sequences of GHRH or the functional biological equivalents thereof is directly into the cells of the subject by the process of in vivo electroporation. A decrease the body fat proportion and an increase in lean body mass (“LBM”), or both of a subject is achieved by the delivery of GHRH or functional biological equivalent thereof as described herein by into the subject as recombinant proteins. In addition, an increase in bone density and improvement in the rate of bone healing is also achieved.

  本发明涉及一种降低受试者体脂比例、增加瘦体重（"LBM"）、增加骨密度或提高骨愈合率或所有方面的方法。总的来说，本发明的实施方案可以通过将编码 GHRH 或其功能生物等效物的异源核酸序列递送到受试者的细胞中，并使编码基因在受试者体内被修饰的细胞中表达来实现。例如，当这种核酸序列被输送到受试者的特定细胞中时，可实现组织特异性组成型表达。此外，GHRH 或其功能生物等效基因的外部调控可以通过利用诱导启动子来实现，诱导启动子由分子开关分子调控，而分子开关分子则给予受试者。将 GHRH 或其功能生物等效物的组成型或诱导型核酸编码序列直接注入受试者细胞的首选方法是体内电穿孔法。通过将本文所述的 GHRH 或其功能性生物等效物作为重组蛋白送入受试者体内，可降低受试者的体脂比例，增加瘦体重（"LBM"），或两者兼而有之。此外，还能增加骨密度和提高骨愈合率。
• Reducing culling in herd animals growth hormone releasing hormone (GHRH)
  申请人：ADViSYS, Inc.

  公开号：US20040204358A1

  公开（公告）日：2004-10-14

  One aspect of the current invention is a method of decreasing an involuntary cull rate in farm animals, wherein the involuntary cull results from infection, disease, morbidity, or mortality. Additionally, milk production, animal welfare, and body condition scores are improved by utilizing methodology that administers the isolated nucleic acid expression construct encoding a GHRH or functional biological equivalent to an animal through a parenteral route of administration. Following a single dose of nucleic acid expression vector, animals are healthier and effects are demonstrated long term without additional administration(s) of the expression construct.

  本发明的一个方面是降低农场动物非自愿宰杀率的方法，其中非自愿宰杀是由感染、疾病、发病率或死亡率引起的。此外，利用通过非肠道给药途径将编码 GHRH 或功能生物等效物的分离核酸表达构建体给药动物的方法，可提高产奶量、动物福利和体况评分。单剂量核酸表达载体给药后，动物会更健康，而且效果明显，无需再给药。
• Enhanced secretion / retention of growth hormone releasing hormone (GHRH) from muscle cells by species-specific signal peptide
  申请人：Draghia-Akli Ruxandra

  公开号：US20050171046A1

  公开（公告）日：2005-08-04

  One aspect of the current invention is a method designing and using species-specific or synthetic signal peptides and GHRH sequences for the purpose of preventing and/or treating chronic illness in a subject by utilizing methodology that administers a single dose of nucleic acid expression vector or nucleic acid expression construct encoding a GHRH or functional biological equivalent to a subject through a parenteral route of administration.

  本发明的一个方面是一种设计和使用物种特异性或合成信号肽和GHRH序列的方法，目的是通过非肠道给药途径向受试者施用单剂量的编码GHRH或功能生物等效物的核酸表达载体或核酸表达构建体，从而预防和/或治疗受试者的慢性疾病。